MicroPort® Lifesciences Attends 2017 CEA Annual Meeting

Shanghai, China – From July 7 to July 8, Shanghai MicroPort Lifesciences Co., Ltd. ("MicroPort® Lifesciences") attended the 2017 Annual Meeting of Chinese Endocrinologist Association ("CEA") in Shanghai. More than 2,500 endocrinologists participated in the meeting and exchanged ideas regarding the clinical and academic advancement in endocrinology as well as the prevention and treatment of chronic diseases.
On July 7, Professor Shouyue Sun of Shanghai Ruijin Hospital of Shanghai Jiao Tong University gave a lecture on "Clinical Management of Gonadotropin-releasing Hormone ("GnRH") Pulsatile Therapy." Professor Sun explained the R&D progress and clinical application of GnRH pulsatile pump as well as the screening and diagnostic criteria of Idiopathic Hypogonadotropic Hypogonadism ("IHH"). Meanwhile, he briefed the application of GnRH pulsatile pump in applications other than IHH, such as polycystic ovary syndrome, central secondary amenorrhea, and pituitary stalk interruption syndrome. In particular, Professor Sun introduced La Fenice® Hypophyseal Hormone Infusion Pump, which was jointly developed by MicroPort® Lifesciences and CEA President Guang Ning of Shanghai Ruijin Hospital. Equipped with pulsatile infusion via micro pump technology, La Fenice® Hypophyseal Hormone Infusion Pump works as an artificial hypothalamus – it stimulates hypophysis to excrete follicle-stimulating hormone ("FSH") or luteinizing hormone ("LH") by simulating pulsatile excretion of GnRH in order to make patients recover from abnormally physiological regulated function. It is the first domestically developed GnRH pulsatile pump. According to Professor Sun, by the end of 2016, a total of 1,200 male patients and 200 female patients have used La Fenice® Hypophyseal Hormone Infusion Pump and have achieved great treatment effect. During his lecture, the attendees also had hot discussions with Professor Sun about the treatment of difficult IHH cases and clinical applications of GnRH pulsatile pump.
During the CEA Annual Meeting, Academician Guang Ning and other experts visited MicroPort® Lifesciences booth and inquired for more information of La Fenice® Hypophyseal Hormone Infusion Pump and La Fenice® Insulin Pump, with special attention to the clinical applications of the two devices. Academician Ning said: "La Fenice® Hypophyseal Hormone Infusion Pump has good efficacy in treating IHH, certain polycystic ovary syndrome, and central secondary amenorrhea. I hope that MicroPort® Lifesciences will further enhance the clinical management of La Fenice® Hypophyseal Hormone Infusion Pump to benefit more patients suffering from hypothalamus-hypophysis-sex gland function disorders."